Clinical Trial Update: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration [Phase 3]

View source ↗

Summary

SWOG's Phase 3 trial S1803 is evaluating lenalidomide with or without daratumumab/rHuPH20 as post-autologous stem cell transplant maintenance for multiple myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• Hylenex recombinant human hyaluronidase (recombinant human hyaluronidase PH20)
• Revlimid (lenalidomide)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING